Drug intelligence / Profile preview

MG010

Development stage: Unknown
Lead developer: Metagone Biotech Australia
Modality: Small Molecules
Administration: Oral

Overview

MG010 is a small molecule C-Raf (RAF1) inhibitor developed by Metagone Biotech Australia Pty Ltd. It is a novel salted formulation of the compound GW5074. MG010 specifically targets mitochondrial C-Raf and the phosphorylated Death-Associated Protein Kinase (DAPK) complex within cancer cells, leading to mitochondrial dysfunction and subsequent apoptosis. It is primarily being investigated as an oral therapy in combination with the multi-kinase inhibitor sorafenib (the combination is designated MGD-1609) for the treatment of advanced or metastatic solid tumors, including colorectal cancer, hepatocellular carcinoma, renal cell carcinoma, and non-small cell lung carcinoma.

Other names: GW5074 salted formGW-5074 salted formGW 5074 salted form

Targets

RAF1 (c-Raf-1 (Y340D/Y341D))

Beyond the preview

Go deeper on MG010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MG010.

Explore the full profile